title: Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.
abstract: This study investigated whether conformal radiotherapy affects hepatitis B virus (HBV) reactivation, and the risk factors for HBV reactivation in patients with HBV-related hepatocellular carcinoma (HCC). Sixty-nine patients with HCC were included in this retrospective study. Before radiotherapy (RT), all patients underwent imaging examinations and some baseline examinations, including CBC, liver function test, renal function test, α-fetoprotein level, hepatitis B (HB) surface antigen, HB surface Ab, HB e antigen, HB e Ab, and serum HBV DNA quantification. During the period of RT and at least 16 weeks after the end of RT, CBCs were carried out weekly and the other tests were monitored monthly or more frequently if necessary. The clinical features and dosimetric parameters of RT were recorded. Univariate and multivariate logistic regression algorithms were used to analyze the risk factors of HBV reactivation. The incidence of complications in the study population was as follows: radiation-induced liver disease, 17.4%; HBV reactivation, 24.6%; and HBV reactivation-induced hepatitis, 21.7%. The HBV DNA level and dose volume parameters including normal liver volume, V20, and mean dose were associated with HBV reactivation. There was a relatively high incidence of HBV reactivation in HCC patients after the end of conformal RT. The serum HBV DNA level and some dosimetric parameters related to normal liver, including normal liver volume, V20, and mean dose, were the prognosis factors of HBV reactivation and should be carefully considered before conformal RT.
authors.affiliation: Department of Radiation Oncology VI, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Shandong's Key Laboratory of Radiation Oncology, Jinan, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Fan
authors.forename: Yanda
authors.initials: Y
authors.lastname: Lu
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Hongsheng
authors.initials: H
authors.lastname: Li
authors.forename: Baosheng
authors.initials: B
authors.lastname: Li
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006515:Hepatitis B virus / Q000235:genetics / Q000254:growth & development / Q000528:radiation effects*; D019694:Hepatitis B, Chronic / Q000821:virology*; D006801:Humans; D008099:Liver / Q000473:pathology / Q000821:virology; D008107:Liver Diseases / Q000209:etiology; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D020266:Radiotherapy, Conformal / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors; D014775:Virus Activation / Q000528:radiation effects*
chemical_list: D004279:DNA, Viral
keywords: Hepatitis B virus; hepatocellular carcinoma; radiation-induced liver disease; radiotherapy; reactivation